<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>471-SIROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIROLIMUS" rxcui="35302">
<ATC code="L04AA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>471-SIROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIROLIMUS" rxcui="35302">
<ATC code="L04AA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
<ATC code="C08DA51" />
<ATC code="C09BB10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.</COMMENT>
</INTERACTION>
</INTERACTIONS>
